16 December 2013 1 9K Report

Do You analyze concentration of CD 133+/34- endothelial progenitor cells

in the bone marrow and in stem cell products before administration in the critically ischemic limb of the patients with critical limb ischemia? Do you examine the viability of the stem cells before their administration to the ischemic limb?

More Peter Kubisz's questions See All
Similar questions and discussions